A 42-year-old woman with poorly controlled type 2 diabetes mellitus presents with a chronic, non-healing ulcer on her left foot that has been present for 8 weeks. The wound shows delayed epithelialization, minimal granulation tissue formation, and impaired angiogenesis. Which agent is the drug of choice to accelerate wound healing in this diabetic ulcer?

Explanation

## Pharmacological Enhancement of Wound Healing in Diabetic Ulcers **Key Point:** Becaplermin (recombinant platelet-derived growth factor, rPDGF) is the FDA-approved and evidence-based drug of choice for accelerating healing in chronic diabetic foot ulcers by promoting fibroblast proliferation, angiogenesis, and collagen deposition. ### Mechanism & Evidence for Becaplermin 1. **Growth Factor Replacement**: Recombinant PDGF-BB mimics the natural growth factor depleted in chronic diabetic wounds. 2. **Cellular Effects**: - Stimulates fibroblast chemotaxis and proliferation - Promotes angiogenesis (new blood vessel formation) - Enhances collagen synthesis and remodeling 3. **Clinical Efficacy**: Randomized trials show ~50% reduction in time to complete healing and improved ulcer closure rates compared to placebo. 4. **Application**: Topical gel applied to the ulcer bed; requires adequate debridement and moist wound environment. ### Why Becaplermin is Superior | Agent | Mechanism | Efficacy in Diabetic Ulcer | Role | |-------|-----------|---------------------------|------| | **Becaplermin (rPDGF)** | Growth factor replacement | ✓ Proven acceleration of healing | **Drug of choice** | | **Vitamin C** | Antioxidant, collagen cofactor | Minimal; supportive only | Adjunctive | | **Corticosteroids** | Anti-inflammatory | ✗ Impairs healing; contraindicated | Avoid | | **Antibiotics** | Infection control | Necessary if infected; not healing-promoting | Supportive | **Clinical Pearl:** Diabetic ulcers fail to heal due to impaired growth factor signaling, reduced angiogenesis, and chronic inflammation. Becaplermin directly addresses the pathophysiology by replacing the deficient PDGF, making it the only FDA-approved growth factor therapy for this indication. **High-Yield:** The three pillars of diabetic ulcer management are: (1) glycemic control, (2) pressure relief/offloading, and (3) growth factor therapy (becaplermin). Becaplermin is indicated when conservative measures and infection control alone are insufficient. **Warning:** Becaplermin requires: - Clean, debrided wound bed (no necrotic tissue) - Moist wound environment - Adequate blood supply (ABI > 0.7) - Absence of active infection Do NOT use in wounds with signs of osteomyelitis or severe vascular insufficiency.